A network meta-analysis of randomized controlled trials of patients with atrial fibrillation found that direct oral anticoagulant (DOAC) and P2Y12 inhibitor therapy post-PCI was associated with reduced bleeding risk compared to vitamin K antagonist plus DAPT, without a significant difference in major adverse cardiovascular events.35 Here, P2RY12 is linked to atrial fibrillation.